| Price | 55.00p on 13-01-2026 at 09:13:25 |
|---|---|
| Change | -1.00p -1.79% |
| Buy | 56.00p |
| Sell | 54.00p |
| Last Trade: | Buy 850.00 at 55.3972p |
| Day's Volume: | 1,058,141 |
| Last Close: | 56.00p |
| Open: | 56.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 54.50p - 56.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £238.51m |
| VWAP: | 55.53136p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 850 | 55.3972p | Ordinary |
09:13:24 - 13-Jan-26 |
| Buy* | 10,000 | 55.40p | Ordinary |
09:12:32 - 13-Jan-26 |
| Buy* | 1,787 | 55.40p | Ordinary |
09:12:31 - 13-Jan-26 |
| Sell* | 5,000 | 54.575p | Ordinary |
09:07:36 - 13-Jan-26 |
| Buy* | 272 | 55.4722p | Ordinary |
09:07:19 - 13-Jan-26 |
| Sell* | 22,500 | 54.575p | Ordinary |
09:07:06 - 13-Jan-26 |
| Sell* | 25,000 | 54.60p | Ordinary |
09:06:45 - 13-Jan-26 |
| Buy* | 360 | 55.475p | Ordinary |
09:05:38 - 13-Jan-26 |
| Buy* | 542 | 55.5272p | Ordinary |
09:05:03 - 13-Jan-26 |
| Buy* | 18,750 | 55.50p | Ordinary |
09:05:02 - 13-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
